GeneICE – CRT Research Update

For immediate release: 17th January 2008

                                  VALIRX PLC                                   

                          ("ValiRx" or the "Company")                          

                         GeneICE - CRT Research Update                         

- First Phase of Pre-Clinicals Successfully Completed, Second Phase To Begin - 

ValiRx (AIM: VAL), the cancer therapeutics company, is pleased to announce that
further to the announcements made on [14] May 2007 and [10] September 2007, its
subsidiary, Cronos Therapeutics Ltd ("Cronos"), in conjunction with Cancer
Research Technology Limited ("CRT"), has completed the final part of the first
phase of pre-clinical studies on one of its cancer therapeutics development
programmes.

Under this work, the original GeneICE therapeutics molecule researched has
successfully been shown to trigger cell death in ovarian, pancreatic and
prostate cancer cells.

As a result, the development of therapeutic treatments based on this GeneICE
compound can now commence; this work is being fully funded by a development
grant whereby ValiRx retains all commercial rights. It is anticipated that
should this next phase go according to plan, the Company would be in a position
to begin the regulatory filings in relation to Phase 1 human trials in the
fourth quarter of 2008.

In addition, Cronos has expanded its product portfolio with the development of
a second GeneICE molecule, which according to the Company has performed well in
initial tests.

Dr Satu Vainikka, CEO of ValiRx, commented:

"We are delighted with the progress being made with CRT. The GeneICE
technology, with its European and US patent rights secured, remains a central
focus for the Company and provides the rationale for us developing
complementary diagnostic technologies both in the UK and through our research
and commercialisation division, ValiBIO S.A., in Belgium. We look forward to
the steady development of our R&D programmes in 2008."

                                   --Ends--                                    

Information on Cancer Research Technology Limited

CRT is a specialist technology transfer company which aims to develop new
discoveries in cancer research for the benefit of cancer patients. CRT is
wholly owned by Cancer Research UK, the largest independent funder of cancer
research in the world. CRT works closely with leading international cancer
scientists and their institutes to protect intellectual property arising from
their research and to establish links with commercial partners. CRT facilitates
the discovery, development and marketing of new cancer therapeutics, vaccines,
diagnostics and enabling technologies. Further information about CRT can be
found at www.cancertechnology.com

About ValiRx plc

ValiRx is a biopharmaceutical development company that is building a portfolio
of complementary cancer-related therapeutic and diagnostic technologies. It
currently holds a worldwide exclusive license for Nucleosomics, the early stage
oncology diagnostics technology, and has majority stakes in Cronos and ValiBIO
SA:

  * Cronos holds worldwide exclusive licenses to two innovative and potentially
    market changing technologies, GeneICE and HyperGenomicsTM, and is
    developing further novel cancer therapies;
   
  * ValiBIO SA is a Belgium joint venture between ValiRx and BIO.be focusing on
    the development and commercialisation of products in the epigenomics
    sector, the first products to be put into development being HyperGenomics
    and Nucleosomics. ValiRx has a 77% majority holding in the company.
   
ValiRx is headquartered in London, England. Further information can be found at
www.valirx.com

Contact Details:

     ValiRx Plc          WH Ireland         GTH Communications    
                                                                  
  Dr Satu Vainikka     David Youngman        Toby Hall / Jade     
                                                Mamarbachi        
                                                                  
[phone]   [phone]     [phone]   
                            2174